Immune-related pneumonitis with nivolumab and ipilimumab during the COVID-19 pandemic
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Dear Editor,The city of São Paulo is the epicentre of the coronavirus disease 2019 (COVID-19) pandemic in South America. Until May 24th, 2020, a total 49,306 confirmed cases and 3550 deaths were attributted to the new severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2) in the city. As such, patients with acute respiratory symptoms with hospitalisation criteria are usually admitted under the presumed diagnosis of COVID-19, until at least one negative reverse transcriptase polymerase chain reaction (RT-PCR) test. However, patients undergoing immune checkpoint inhibitors are at risk for immune-related pneumonitis. This currently poses a diagnostic challenge, as symptoms and computerised tomography (CT) findings often overlap. Steroids, the main treatment modality for immune-related adverse events, are cautioned against for COVID-19, potentially causing delay in proper management of a severe condition.
European Journal of Cancer , éditorial en libre accès, 2019